Skip to main content

Table 1 Table showing the characteristics of the humansamples analysed in the present study. The total number (N) ofsamples and the median age with its interquartile range areshown for every group: Young and aged controls (Con),asymptomatic ALS patients (Asympt.), patients carrying a knowngenetic mutation (gALS) and patients without any identifiedgenetic mutation (sALS)

From: Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis

  Con (young) Con (aged) Asympt. ALS gALS sALS
N (f/m) 24 (14/10) 32 (13/19) 21 (14/7) 38 (14/24) 70 (25/45)
Age (yr) 42 (31-50) 63 (57-72) 45 (35-51) 59 (51-67) 65 (56-70)